PLoS ONE (Jan 2016)

Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination.

  • Joseph E Tota,
  • Mengzhu Jiang,
  • Agnihotram V Ramanakumar,
  • Stephen D Walter,
  • Jay S Kaufman,
  • François Coutlée,
  • Harriet Richardson,
  • Ann N Burchell,
  • Anita Koushik,
  • Marie Hélène Mayrand,
  • Luisa L Villa,
  • Eduardo L Franco

DOI
https://doi.org/10.1371/journal.pone.0166329
Journal volume & issue
Vol. 11, no. 12
p. e0166329

Abstract

Read online

Millions of women have been vaccinated with one of two first-generation human papillomavirus (HPV) vaccines. Both vaccines remain in use and target two oncogenic types (HPVs 16 and 18); however, if these types naturally compete with others that are not targeted, type replacement may occur following reductions in the circulating prevalence of targeted types. To explore the potential for type replacement, we evaluated natural HPV type competition in unvaccinated females.Valid HPV DNA typing information was available from five epidemiological studies conducted in Canada and Brazil (n = 14,685; enrollment across studies took place between1993 and 2010), which used similar consensus-primer PCR assays, capable of detecting up to 40 HPV types. A total of 38,088 cervicovaginal specimens were available for inclusion in our analyses evaluating HPV type-type interactions involving vaccine-targeted types (6, 11, 16, and 18), and infection with each of the other HPV types.Across the studies, the average age of participants ranged from 21.0 to 43.7 years. HPV16 was the most common type (prevalence range: 1.0% to 13.8%), and in general HPV types were more likely to be detected as part of a multiple infection than as single infections. In our analyses focusing on each of the vaccine-targeted HPV types separately, many significant positive associations were observed (particularly involving HPV16); however, we did not observe any statistically significant negative associations.Our findings suggest that natural HPV type competition does not exist, and that type replacement is unlikely to occur in vaccinated populations.